Document is current
Any future updates will be listed below
-
Authors
Albrecht, Alexander
Taubmann, Jule
Minopoulou, Ioanna
Hatscher, Lukas
Kleinert, Stefan
Mühlensiepen, Felix
Welcker, Martin
Leipe, Jan
Schulz, Nils
Klemm, Philipp
Hueber, Axel
Schett, Georg
Kuhn, Sebastian
Labinsky, Hannah
Knitza, Johannes https://orcid.org/0000-0001-9695-0657
-
Funding
Funding for this research was provided by:
AbbVie Deutschland
- License Information
-
More Information
Article History
Received: 10 November 2024
Accepted: 2 January 2025
First Online: 21 January 2025
Declarations
:
: Johannes Knitza declares research support from Abbvie, GSK, and Vila Health; and honoraria and consulting fees from Abbvie, AstraZeneca, BMS, Boehringer Ingelheim, Chugai, GAIA, Galapagos, GSK, Janssen, Lilly, Medac, Novartis, Pfizer, Sobi, Rheumaakademie, UCB, Vila Health, and Werfen. Sebastian Kuhn is founder and shareholder of MED.digital GmbH. Stefan Kleinert and Martin Welcker are members of RheumaDatenRheport GbR which holds shares in the distribution company for the rheumatological application Rhecord. Rhecord was not part of this study. Felix Mühlensiepen declares research support from Abbvie and Novartis. The remaining authors, Alexander Albrecht, Jule Taubmann, Ioanna Minopoulou, Lukas Hatscher, Jan Leipe, Nils Schulz, Philipp Klemm, Axel Hueber, Georg Schett, and Hannah Labinsky, declare no competing interests.
: The DiGAReal registry was approved by the Institutional Review Board of the Medical Faculty of the University of Erlangen-Nürnberg, Germany (Reg No. 22-113-1-B). All procedures followed relevant guidelines and regulations, including the Declaration of Helsinki. Informed consent was obtained from all individual respondents included in the study.
